Alnylam Pharmaceuticals, Inc.
ALNY· Nasdaq
ALNYAlnylam Pharmaceuticals, Inc.
Filed Feb 15, 2017 · 10-K · 46 days after period end · 0001564590-17-001649
| Metric | Q4 2016 | Q4 2015 | Q4 2014 | Q4 2013 |
|---|---|---|---|---|
| Net Income | -$112.93M | -$90.72M | -$21.39M | -$32.36M |
| EPS Diluted | -$1.32 | -$1.07 | -$0.28 | -$0.51 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Alnylam Pharmaceuticals, Inc. · CIK 1178670 · Engraved from SEC EDGAR
ended Dec 31, 2016 · filed Feb 15, 2017 · 46 d after period end
